Clinical Trial Detail

NCT ID NCT02362594
Title Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.